
KIR AND HLA HAPLOTYPE ANALYSIS IN A FAMILY
LACKING THE KIR 2DL1-2DP1 GENES Vojvodić S, Ademović-Sazdanić D *Corresponding Author: Associate Professor Svetlana Vojvodić, Institute for Blood Transfusion of Vojvodina,
Tissue Typing Compartment, Medical Faculty of the University of Novi Sad, Hajduk Veljkova 9a, 21000 Novi
Sad, Serbia; Tel: +381-21-4877-963, Fax: +381-21-4877-978; E-mail: svetlana.vojvodic021@gmail.com page: 55
|
INTRODUCTION
Natural killer (NK) cells of innate immunity and
CD8+ cytotoxic T cells (CTL) of adaptive immunity
are professional killer cells that are necessary for
defense against virus-infected or tumor-transformed
cells. Natural killer cells recognize and kill target
cells with absent or altered expression of human leukocyte
antigen (HLA) class I molecules. This missing
self recognition makes NK cells able to eliminate
tumoral and virus-infected cells that lack self HLA
class I molecules. Furthermore, in the allogeneic
context of hematopoietic stem cell transplantation, NK cells from the donor can be alloreactive against
recipient cells. This NK cell alloreactivity is mediated
by a balance between activating and inhibitory
signals and leads to cytotoxicity and production of
proinflammatory cytokines, such as IFN-γ. Receptors
of HLA class I molecules involved in recognition
of target cells partly belong to the killer cell Ig-like
receptor (KIR) family, encoded by 14 genes and
two pseudogenes located on chromosome 19q13.4,
within a 100 to 200 kb region of the leukocyte receptor
complex (LRC) [1-5]. The number of genes
present in KIR haplotypes is variable, however four
genes (KIR 3DL3, KIR3DP1, KIR2DL4, KIR3DL2)
are present on virtually all haplotypes, and are thus
considered as framework genes. Two major classes
of KIR haplotypes (A and B) have been identified,
which is unique to the human species and that were
shown to have differential associations with disease
and reproductive success. The A haplotype
contains four genes in addition to the framework
genes (KIR2DL1, KIR2DL3, KIR3DL1, KIR2DS4),
representing a predominantly inhibitory haplotype.
There are many B haplotypes, containing various
combinations of the activating KIR genes [1-3,6-9].
In addition to the substantial variation in gene content
across haplotypes, each KIR gene itself exhibits
considerable nucleotide sequence polymorphism
explaining why the genomic diversity of the human
KIR gene family is its important characteristic attributed
to the variability in both gene numbers and
allelic polymorphism [7,9-11]. Every KIR haplotype
is a combination of a centromeric and a telomeric
KIR gene motif. DNA sequencing of single copies
of chromosome 19 [8,12] and family segregation
analysis [13,14] have defined three common
centromeric (Cen-A1, Cen-B1, Cen-B2) and two
common telomeric (Tel-A1 and Tel-B1) haplotype
structures based on the presence and absence of specific
KIR genes. As examples, Cen-A1 is comprised
of KIR3DL3~KIR2DL3~KIR2DP1~KIR2DL1~KIR
3DP1 in this gene order, whereas Tel-A1 includes
KIR2DL4~ KIR3DL1~KIR2DS4~KIR3DL2. In this
report, we present a detailed HLA and KIR haplotype
analysis of a family having rare KIR genotype. All
members of the family described here displayed a
greater degree of diversity of KIR genetic profiles,
that indicates further complexity of underlying haplotypes;
in this respect, we described six individuals
(grandfather, mother, father and three offspring),
who possess an incomplete KIR haplotype with the
3DP1 variant allele (due to lack of 2DP1-2DL1 alleles).
The aim of the presented case study was to
determine possible explanation of rare KIR genotype
present in patient, siblings and parents of the patient,
through the segregation KIR analysis in patient’s
grandfather and grandmothers.
|
|
|
|



 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|
|